Cyclacel Confirms Nasdaq Listing for Common Stock

TL;DR

**CYCC confirms Nasdaq listing for common stock, business as usual.**

AI Summary

Cyclacel Pharmaceuticals, Inc. filed an 8-K on January 4, 2024, to update its registered securities. The filing confirms that its Common Stock, with a par value of $0.001 per share, is traded under the symbol CYCC on The Nasdaq Capital Market. It also notes the existence of Preferred Stock, also with a $0.001 par value. This matters to investors as it reaffirms the company's listing on a major exchange, providing liquidity and visibility for its common stock, which is crucial for current and potential shareholders.

Why It Matters

This filing confirms Cyclacel's continued listing on The Nasdaq Capital Market, which is important for the liquidity and accessibility of its common stock for investors.

Risk Assessment

Risk Level: low — This filing is purely administrative, confirming existing security registrations, and introduces no new financial or operational risks.

Analyst Insight

Investors should note this administrative filing confirms the company's current listing status but provides no new operational or financial data to influence investment decisions. It's a routine update.

Key Numbers

• $0.001 — Par value per share (Applies to both Common Stock and Preferred Stock of Cyclacel Pharmaceuticals, Inc.)

Key Players & Entities

• Cyclacel Pharmaceuticals, Inc. (company) — the registrant filing the 8-K
• CYCC (company) — trading symbol for Common Stock
• The Nasdaq Capital Market (company) — exchange where Common Stock is registered
• $0.001 (dollar_amount) — par value per share for Common Stock and Preferred Stock
• January 4, 2024 (date) — date of earliest event reported and filing date

Forward-Looking Statements

• Cyclacel Pharmaceuticals, Inc. will maintain its listing on The Nasdaq Capital Market. (Cyclacel Pharmaceuticals, Inc.) — high confidence, target: 2025-01-04

FAQ

Key Financial Figures

• $0.001 — ich registered Common Stock, par value $0.001 per share CYCC The Nasdaq Capital Ma
• $1.00 — are, to maintain a minimum bid price of $1.00 per share for continued listing on the

Filing Documents

• tm242057d1_8k.htm (8-K) — 26KB
• 0001104659-24-001351.txt ( ) — 239KB
• cycc-20240104.xsd (EX-101.SCH) — 3KB
• cycc-20240104_def.xml (EX-101.DEF) — 26KB
• cycc-20240104_lab.xml (EX-101.LAB) — 36KB
• cycc-20240104_pre.xml (EX-101.PRE) — 25KB
• tm242057d1_8k_htm.xml (XML) — 5KB

01 Other Events

Item 8.01 Other Events. As previously disclosed on the Current Report on Form 8-K filed with the Securities and Exchange Commission on July 7, 2023, Cyclacel Pharmaceuticals, Inc. (the "Company") received a letter from the Listing Qualifications Staff (the "Staff") of The Nasdaq Stock Market, LLC ("Nasdaq") notifying the Company that Nasdaq had granted the Company a 180-day extension, or until January 2, 2024, to regain compliance with the requirement for the Company's common stock, par value $0.001 per share, to maintain a minimum bid price of $1.00 per share for continued listing on the Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2). On January 4, 2024, the Company received a minimum bid price compliance letter from the Staff confirming the Company has regained compliance with Listing Rule 5550(a)(2), and that the matter is now closed.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. CYCLACEL PHARMACEUTICALS, INC. By: /s/ Paul McBarron Name: Paul McBarron Title: Executive Vice President-Finance, Chief Financial Officer and Chief Operating Officer Date: January 4, 2024

View Full Filing

View this 8-K filing on SEC EDGAR